Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy?

AIDS

Volumn 19, Issue 11, 2005, Pages 1201-1206

  Breen, Ronan A M ^a   Smith, Colette J ^b   Cropley, Ian ^a   Johnson, Margaret A ^a   Lipman, Marc C I ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

HIV infection; Immune reconstitution; Tuberculosis; Tuberculosis treatment anti retroviral therapy

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION RISK; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYNDROME; TUBERCULOSIS;

EID: 23044510978     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000176221.33237.67     Document Type: Article

References (21)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34:543-546.
3. Girardi E, Antonucci G, Vanacore P, Libanore M, Errante I, Matteelli A, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14:1985-1991.
4. Barry SM, Lipman MCI, Deery AR, Johnson MA, Janossy G. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Medicine 2002; 3:207-211.
5. Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351:252-255.
6. Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998; 125:292-300.
7. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following anti-retroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157-161.
8. Breen RAM, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson MA, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59:704-707.
9. Goldsack NR, Allen S, Lipman MCI. Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex Transm Infect 2003; 79:337-338.
10. Sabin CA, Lampe F, Chaloner C, Madge SJ, Lipman MC, Youle M, et al. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic. HIV Medicine 2003; 4:87-93.
11. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002; 347:1860-1866.
12. Girardi E, Palmieri F, Cingolani A, Ammassari A, Petrosillo N, Gillini L, et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:326-331.
13. Mohammed A, Ehrlich R, Wood R, Cilliers F, Maartens G. Screening for tuberculosis in adults with advanced HIV infection prior to preventative therapy. Int J Tuberc Lung Dis 2004; 8:792-795.
14. Price P, Morahan G, Huang D, Stone E, Cheong KY, Castley A, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002; 16:2043-2047.
15. Cooney EL. Clinical indicators of immune restoration following highly active anti-retroviral therapy. Clin Infect Dis 2002; 34:224-233.
16. Barry SM, Lipman MCI, Bannister B, Johnson MA, Janossy G. Purified protein derivivative-activated type 1 cytokine-producing CD4+ T lymphocytes in the lung: a characteristic feature of active pulmonary and non-pulmonary TB. J Infect Dis 2003; 187:243-250.
17. Kerbiriou L, Ustianowski A, Johnson MA, Gillespie SH, Miller RF, Lipman MCI. Human immunodeficiency virus type 1-related pulmonary Mycobacterium xenopi infection: a need to treat? Clin Infect Dis 2003; 37:1250-1254.
18. Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tansuphaswswadikul S, Bowonwatanuwong C. Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. AIDS 2003; 17:2129-2130.
19. Tassie J-M, Szumilin E, Calmy A, Goemare E. Highly active antiretroviral in resource-poor settings: the experience of Médecins Sans Frontières. AIDS 2003; 17:1995-1997.
20. World Health Organisation. The WHO and UNAIDS Global Initiative to Provide Antiretroviral Therapy to 3 million people with HIV/AIDS in Developing Countries by the End of 2005. Geneva, Switzerland: World Health Organisation; 2003. Available at: http://www.who.int/3by5/en
21. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis. Arch Intern Med 2003; 163:1009-1021.